APYX (Apyx Medical) Debt-to-Asset : 0.65 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APYX Apyx Medical Corp APYX
72 GF Score
Price $2.90
GF Value $2.20
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Apyx Medical Debt-to-Asset?

Apyx Medical APYX +0.35% 72 Debt-to-Asset is 0.65 as of Jun. 2026. GuruFocus rates APYX with a GF Score™ of 72/100 and a GF Value™ of $2.20 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Apyx Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.47 Mil. Apyx Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $39.16 Mil. Apyx Medical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $61.07 Mil. Apyx Medical's debt to asset for the quarter that ended in Jun. 2026 was 0.65.

Apyx Medical  (NAS:APYX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Apyx Medical Debt-to-Asset Related Terms

Apyx Medical Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Apyx Medical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apyx Medical Debt-to-Asset Chart

Apyx Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.49 0.60 0.59

Apyx Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.68 0.59 0.63 0.65

APYX vs MXCT, QTRX, OWLT: Debt-to-Asset Comparison

For the Medical Devices subindustry, Apyx Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apyx Medical Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Debt-to-Asset falls into.


APYX
72GF Score
Apyx Medical Corp APYX
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apyx Medical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Apyx Medical's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.428 + 38.912) / 66.84
=0.59

Apyx Medical's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.472 + 39.158) / 61.072
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.65 mean?
Apyx Medical (APYX) has a Debt-to-Asset of 0.65 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Apyx Medical and its competitors.
Is Apyx Medical's Debt-to-Asset too high?
Apyx Medical's current Debt-to-Asset is 0.65. Overall, Apyx Medical has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Debt-to-Asset compare to MXCT and QTRX?
Apyx Medical's Debt-to-Asset of 0.65 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Apyx Medical and its competitors. Apyx Medical's current Debt-to-Asset is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Based on GuruFocus' analysis, Apyx Medical (APYX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.20, compared to a current price of $2.90 — trading 31.8% above its estimated fair value. The current Debt-to-Asset is 0.65. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Apyx Medical (APYX), the current Debt-to-Asset is 0.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apyx Medical (APYX) Overvalued in 2026?

Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued. The current stock price of $2.90 is trading 31.8% above its estimated GF Value™ of $2.20. GuruFocus considers Apyx Medical to be Significantly Overvalued.

Key valuation signals for APYX:

  • Debt-to-Asset: 0.65
  • GF Value™: $2.20 vs. price of $2.90 (31.8% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the APYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apyx Medical Business Description

Other Exchanges BOV:Germany
Address 5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score

Get the complete analysis for APYX

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$2.20
GF Value